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Abstract
OBJECTIVE: To investigate the effect of Qiguiyish-
en decoction (QGYS) on the severity of nephropa-
thy.
METHODS: Twenty-four rats were randomly divid-
ed into four groups (Ⅰ,Ⅱ,Ⅲ,Ⅳ) according to the
random number table. Group Ⅰ as control group
did not establish nephropathy model. Groups Ⅱ,Ⅲ, and Ⅳ were intravenously administered Adria-
mycin (7.5 mg/kg) through the tail vein to establish
nephropathy model. QGYS was prepared with the
extracts of Huangqi (Radix Astragali Mongolici), Dan-
ggui (Radix Angelicae Sinensis), Niuxi (Radix Achyran-
this Bidentatae), and Chuanxiong (Rhizoma Chuanx-
iong). GroupⅣ was administered QGYS (2 mL·kg-1·
d-1), groupⅢ was administered benazepril (10 mL·
kg-1·d-1), and group Ⅰ, Ⅱ was administered water
(2 mL·kg-1·d-1) once daily for eight weeks.
RESULTS: QGYS reduced the excretion of urinary
protein and N-acetyl-β-D-glucosaminidase and alle-
viated the accumulation of extracellular matrix
(ECM) in renal tissue. Additionally, QGYS effectively
regulated the levels of transforming growth factor,
tissue inhibitor of matrix metalloproteinase, and
matrix metalloproteinases in the kidney of the rats.
CONCLUSION: QGYS may reduce the accumulation
of ECM in the kidneys of rats with Adriamycin-in-
duced nephropathy.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Most chronic kidney diseases (CKD) are types of
chronic glomerulonephritis (CGN). Chinese herbs in
our decoction have been used to treat CGN for more
than one century. We used a decoction derived from
Huangqi (Radix Astragali Mongolici), Danggui (Radix
Angelicae Sinensis), Niuxi (Radix Achyranthis Bidenta-
tae), and Chuanxiong (Rhizoma Chuanxiong) to treat
CGN. Nephropathy is a kidney disease that includes
glomerulosclerosis (GS) and renal interstitial fibrosis
(RIF). High urine protein is the clinical characteristic
of nephropathy and the accumulation of extracellular
351
JTCM |www. journaltcm. com June 15, 2014 |Volume 34 | Issue 3 |
Wei MG et al. / Experimental Study
matrix (ECM) is the pathological feature. CKDs can
be induced in rats by the injection of Adriamycin
(ADR).1 The abnormal accumulation and deposition
of ECM is the main cause of renal scarring and renal fi-
brosis.2 Matrix metalloproteinases (MMP) are a specif-
ic group of zinc-dependent protein hydrolysis enzymes
that can break down ECM. In renal tissue, tissue inhib-
itors of matrix metalloproteinases (TIMPs) are the spe-
cific inhibitors of MMPs. Recent studies indicate that
MMPs, especially MMP-2 and MMP-9, play a role in
the regulation of kidney ECM metabolism.3,4 In our
study, we studied the treatment effect of QGYS on
Adriamycin-induced nephropathy.
MATERIALS ANDMETHODS
Drugs and chemicals
Drugs and plant material used were: Adriamycin (doxo-
rubicin hydrochloride, Adrim; HaiZheng Pharmaceuti-
cals, Zhejiang, China), Huangqi (Radix Astragali Mon-
golici), Danggui (Radix Angelicae Sinensis), Niuxi (Ra-
dix Achyranthis Bidentatae), and Chuanxiong (Rhizoma
Chuanxiong) (Suzhou Tianling Pharmaceutical Co.,
Ltd., Suzhou, China), and benazepril (Lotensin, Novar-
tis, Beijing, China). All other chemicals and solvents
used in the present experiment were of analytical grade.
The decoction was prepared with the crude herbs
Huangqi (Radix Astragali Mongolici) 600 g, Danggui
(Radix Angelicae Sinensis) 200 g, Niuxi (Radix Achyran-
this Bidentatae) 200 g, and Chuanxiong (Rhizoma Ch-
uanxiong) 200 g. Herbs were soaked in 2000 mL dis-
tilled water for 30 min, and then boiled it for 30 min.
The decoction was ﬁltered and condensed to 1000 mL.
Professor Jiade Shao, Department of Natural Medi-
cines, the First Affiliate Hospital of Nanjing Tradition-
al Chinese Medicine University School of Pharmaceuti-
cal Sciences, identiﬁed the botanical origin of the four
herbs, and supervised the preparation of the decoction
and quality control of QGYS.
Experimental animals and treatment
Animals were supplied by the Shanghai Laboratory An-
imal Center [certificate of quality SCXK (Shanghai)
2007-0005]. Male SD albino rats (140 ± 10) g were
housed under standard temperature (23℃±1℃), rela-
tive humidity (55%±10%), and 12 h light/12 h dark
cycle with access to food and water ad libitum. The
study was approved by the Animal Ethics Committee
of the First Affiliated Hospital of Soochow University.
Rats were randomly assigned to groupⅠ (sham opera-
tion), group Ⅱ, group Ⅲ, or group Ⅳ according to
the random numble table. GroupsⅡ,Ⅲ, andⅣ were
intravenously administered Adriamycin (7.5 mg/kg)
through the tail vein to establish the nephropathy mod-
el. One week later, group Ⅳ rats were treated with
QGYS, group Ⅲ was given benazepril, and group Ⅱ
was administered the same volume of water once daily
for eight weeks. Benazepril and QGYS were given at
the human equivalent doses of 10 mL·kg-1·d-1 (equal
to 10 mL·kg-1·d-1 in humans) and 1 g·kg-1·d-1 (equal
to 2 mL·kg-1·d-1 in humans), respectively. The dose of
QGYS was selected because it was shown to be the
minimal dose that exhibited a maximal inhibiting ef-
fect on TGF-β1 mRNA expression in Adriamycin-in-
duced nephropathy rats in our preliminary experiment
using 2, 1, and 0.5 g/kg of QGYS.
Testing of urine and blood
Before sacrifice, the rats were placed in metabolic cages
on day 7, 28, 42, and 56 for 24-h urine collection.
Rats remained on a normal diet with an unrestricted
fluid intake. At the end of the experiment, the vol-
ume of urine was measured. Individually collected
urine (5 mL) was centrifuged at 5000 × g for 5 min.
The supernatant was collected and stored at ﹣80℃ .
Blood (3 mL) was obtained from each rat via the abdom-
inal aorta on day 56 and then centrifuged at 5000 ×g at
room temperature for 10 min. The serum was collect-
ed and stored at ﹣80℃ for the detection of serum al-
bumin (SAL), plasma lipids, serum creatinine (SCr),
and blood urea nitrogen (BUN). These indicators were
examined by an automatic biochemistry analyzer
(OLYMPUS AU- 2700, Tokyo, Japan). Radioimmu-
noassay was used for the detection of urine NAG con-
centration. The 24-h urine protein excretion was deter-
mined by urinary protein and 24-h urine volume.
Preparation of kidney samples
In every 2-week experimental period, the body weight
of rats was recorded. At the end of the 8 weeks, ani-
mals were sacrificed. Kidneys were harvested and
weighed after removal of the envelopes. The kidney/
body weight ratio (K/B) was then determined.
Immunohistochemistry analysis
Renal tissue samples were fixed in 10% neutral formal-
dehyde (Bio-no company, Suzhou, China), dehydrated
with ethanol (Bio-no company, Suzhou, China), and
embedded in paraffin. Serial sections (4 μm) were col-
lected sequentially on glass slides (Yao hua glass instru-
ment company, Yanchen, China). Paraffin was re-
moved from the sections with xylene and sections were
rehydrated in graded ethanol. To retrieve antigenicity
from formalin fixation, we incubated the sections for
10 min in 10 mmol/L sodium citrate buffer using a mi-
crowave oven (Midea company, Fushan, China). En-
dogenous peroxidase activity was blocked by further
pretreatment with 3% hydrogen peroxide (H2O2) (Bai-
yun pharmaceutical Co., Ltd., Nanchang, China) and
methanol. Finally, the sections were incubated with pri-
mary monoclonal antibodies against MMP-9,
TIMP-1, fibronectin (FN), and collagen Ⅳ (Col-Ⅳ)
(Abcam compamy, Combridge, USA) overnight at
4℃ . Sections were washed thoroughly in phos-
phate-buffered saline (PBS) and incubated with rabbit
anti-mouse biotinylated second antibody immunoglob-
ulin for 30 min, followed by the avidin-biotin peroxi-
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dase complex. Finally, sections were stained with di-
aminobenzidine (DAB) (Gene compamy, Shanghai,
China). We obtained negative controls by replacing
specific antisera with PBS (Bio-no company, Suzhou,
China). Brownish yellow granular or linear deposits in
the cells or matrix were interpreted as positive areas.
Semi-quantitative evaluation was performed by com-
puter-assisted image analysis (Leica company, Solms,
Germany). The mean optical density of transforming
growth factor-β1 (TGF-β1), MMP-9, TIMP-1, FN,
and Col-Ⅳ was measured at 400× original magnifica-
tion in 30 glomeruli of coded sections for each rat.
General electronics (GE) logic E9 ultrasound diagnosis
system (General Electronics, Wauwatosa, WI, USA)
with a 6-15 MHz linear transducer was used for ultra-
sound scanning. The rats were examined while sedated
in prone position. The transducer was placed gently on
the back beside the spinal column for ultrasonography
of the kidneys. All examinations were performed with
the same ultrasound system parameters. Sonograms of
kidneys were analyzed by Image J software that was de-
signed by the National Institutes of Health (NIH) to
calculate the grayscale value (NIH, Bethesda, USA).
Statistical analysis
Data are expressed as mean±SD. Statistical analysis was
performed using the non-parametric Mann-Whitney
U-test to compare data in different groups. A P-value
0.05 was considered to indicate a statistically signifi-
cant difference. Data were analyzed with SPSS 14.0
(Chicago, IL, USA).
RESULTS
Physical and behavioral effects of ADR on rats
All rats in group I survived and exhibited normal physi-
cal appearances and behavior with smooth fur and
weight gain during the experiments. Conversely, rats in
the other groups had diarrhea and exhibited dull,
coarse hair, lethargy, physical inactivity, and loss of
body weight (Table 1).
Effects of ADR and QGYS on the K/B, serum
albumin, and plasma lipids
In group Ⅱ, the K/B ratio and serum albumin levels
were significantly higher, and plasma lipid levels were
significantly lower than those in group I. However, af-
ter treatment with QGYS for 56 days, the K/B ratio
and the levels of serum albumin were significantly low-
er than group Ⅰ , and the levels of plasma lipids were
significantly higher than groupⅠ (P<0.05, Table 1).
Figure 1 shows renal pathological alteration in the dif-
ferent groups after 12 weeks of intervention. The ultra-
sound grayscale data show significantly greater altera-
tion in Adriamycin-induced nephropathy rats (groupsⅡ, Ⅲ, and Ⅳ) than control rats (group I). Moreover,
groups Ⅲ and Ⅳ, show significantly less alteration
than group Ⅱ (P<0.05). At the end of 8 weeks, the al-
teration in groupⅣ was less than that in groupⅢ (P<
0.05, Table 1).
Through the gray analysis method, we have done quan-
titative analyzed to the renal cortex at different groups.
The results show that QGYS can obviously decrease
the lesion degree of renal cortex in rats by the way of
statistical.
Table 1 BUN, SCr, K/B weight, serum albumin, and plasma lipids for all groups after 56 days ( xˉ ±s)
Group
Ⅰ
Ⅱ
Ⅲ
Ⅳ
n
8
8
8
8
K/B weight
(mg/kg)
3.46±0.19
5.91±0.12
4.85±0.19
4.31±0.28
Serum albumin
(g/L)
21.92±0.85
11.96±1.88
15.02±4.88
14.78±2.65
Plasma lipids
(mmol/L)
0.64±0.22
1.66±1.14
0.66±0.32
0.52±0.30
Date of gray scale
80.20±13.64
130.30±16.22
111.20±13.49
100.70±8.76
BUN
(mmol/L)
6.15±0.57
5.17±0.42
6.01±0.91
6.14±0.77
SCr
(umol/L)
29.66±2.36
22.26±5.36
23.30±7.75
30.10±2.11
Notes: groupⅠ as control group did not establish nephropathy model. GroupsⅡ,Ⅲ, andⅣ were intravenously administered Adriamy-
cin (7.5 mg/kg) through the tail vein to establish nephropathy model. GroupⅣ was administered Qiguiyishen decoction (2 mL·kg-1·d-1);
group Ⅲ was administered benazepril (10 mL·kg-1·d-1); and groupsⅠ, Ⅱ was administered water (2 mL·kg-1·d-1) once daily for eight
weeks. K/B: kidney /body weight ratio; SCr: serum creatinine; BUN: blood urea nitrogen.
Figure 1 Renal pathological alteration in all groups after 12
weeks of intervention (HE, ×400)
Group Ⅰ as control group did not establish nephropathy
model. Groups Ⅱ, Ⅲ, and Ⅳ were intravenously adminis-
tered Adriamycin (7.5 mg/kg) through the tail vein to estab-
lish nephropathy model. GroupⅣ was administered Qiguiy-
ishen decoction (2 mL·kg-1·d-1); groupⅢ was administered
benazepril (10 mL·kg-1·d-1); and groupsⅠ,Ⅱ was adminis-
tered water (2 mL·kg-1·d-1) once daily for eight weeks. HE:
hematoxylin-eosin staining.
A B
C D
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Effects of QGYS on the ratio of urine protein and
NAG
The levels of urine protein were significantly higher in
Adriamycin-induced nephropathy rats than in control
rats. Moreover, the level of urine protein in groups Ⅲ
and Ⅳ, after respective treatment with QGYS and
benazepril, were significantly lower than that in groupⅡ. (P<0.05). After 8 weeks, the urine protein in group
IV was less than 75% of that in group Ⅱ (P<0.05)
(Figure 2). Moreover, significantly increased NAG was
detected in group II, compared with that in each other
group (P<0.05). After treatment with GQYS or benaz-
epril, there was significantly lower NAG than that in
groupⅡ (P<0.05) (Figure 3).
Effects of QGYS on BUN and SCr levels and Col-IV,
FN,TGF-β1,MMP-9, andTIMP-1protein expression
The levels of BUN, SCr were not significantly higher
in group Ⅳ than in group Ⅱ (P>0.05). In group Ⅱ,
glomerular staining for Col-Ⅳ and FN was significant-
ly higher than that in the other groups (P<0.05). How-
ever, glomerular staining for Col-Ⅳ and FN was signif-
icantly lower in QGYS-treated or benazepril-treated
rats (P<0.05). There was also a significant difference
between groups Ⅲ and Ⅳ (P<0.05, Figure 4). In
group Ⅱ, the glomerular staining for TGF-β1 and
TIMP-1 was markedly higher than that in the other
groups (P<0.05). However, glomerular staining for
TGF-β1 and TIMP-1 was significantly lower in
QGYS-treated or benazepril-treated rats (P<0.05).
There was also a significant difference between groupsⅢ and Ⅳ, with group Ⅳ showing much less staining
(P<0.05) (Table 2). At the same time, we found that
group Ⅱ rat glomerular staining for MMP-9 was less
than that in other groups (P<0.05). Glomerular stain-
ing for MMP-9 was significantly higher in QGYS-treat-
ed or benazepril-treated rats than that in group Ⅱ (P<
0.05, Table 2).
DISCUSSION
QGYS contains many active components that have
Ⅰ Ⅱ Ⅲ Ⅳ
s
Figure 2 Trend of 24 h urine protein in the four groups after injection of Adriamycin
GroupⅠ as control group did not establish nephropathy model. GroupsⅡ,Ⅲ, andⅣ were intravenously administered Adriamy-
cin (7.5 mg/kg) through the tail vein to establish nephropathy model. GroupⅣ was administered Qiguiyishen decoction (2 mL·
kg-1·d-1); groupⅢ was administered benazepril (10 mL·kg-1·d-1); and groupsⅠ,Ⅱ was administered water (2 mL·kg-1·d-1) once
daily for eight weeks.
Wei MG et al. / Experimental Study
Figure 3 Trend of urine NAG in the four groups after injection of Adriamycin
GroupⅠ as control group did not establish nephropathy model. GroupsⅡ,Ⅲ, andⅣ were intravenously administered Adriamy-
cin (7.5 mg/kg) through the tail vein to establish nephropathy model. GroupⅣ was administered Qiguiyishen decoction (2 mL·
kg-1·d-1); groupⅢ was administered benazepril (10 mL·kg-1·d-1); and groupsⅠ,Ⅱ was administered water (2 mL·kg-1·d-1) once
daily for eight weeks. NAG: N-acetyl-β-D-glucosaminidase.
Ⅰ Ⅱ Ⅲ Ⅳ
s
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been used for the treatment of hypodynamia and swell-
ing. Regardless of etiology, both glomerulosclerosis and
tubulointerstitial fibrosis are the final common path-
ways of the progression seen in most CKDs.5 Addition-
ally, proteinuria is an independent risk factor of renal
function decline in patients with CKD. Urine NAG
can indicate possible tubular damage and is used for de-
tecting early or minimal damage in proximal tubular
function.6 Antiproteinuric treatments, especially ACE
inhibitors or angiotensin Ⅱ (ARB) receptor blockers,
are instruments to maximize renoprotection.7 Howev-
er, both ACEI or ARB have no effects on the NAG of
renal disease. Thus, benazepril served as the positive
control in this study.
The accumulation of ECM within the kidney is evi-
dence for Adriamycin-induced nephropathy.8 MMPs
are the major enzymes responsible for matrix degrada-
tion in the kidney.9 MMP-9 is a member of the MMP
family, which is engaged in the degradation of collagenⅣ Ⅴ Ⅵ, FN, laminin, and other components of the
extracellular matrix.10 The activities of MMPs are tight-
ly regulated by TIMPs. TIMP-1 is the specific inhibi-
tor of MMP-9 in the kidney.11 Under physiological con-
ditions, MMP-9 and TIMP-1 maintain a dynamic bal-
ance between the synthesis and degradation of ECM.
Chronic kidney disease relevant indicators such as
urine protein and NAG increased in one week after us-
ing doxorubicin tail intravenous injection. What the
level of relevant indicators would increase, it meaned
that the animal model of adriamycin-induced nephrop-
athy was succeed. Through taking drug intervention
would control the progress of disease and achieved
good therapeutic effects.
In our study, rats with Adriamycin-induced nephropa-
thy experienced increases in the levels of urine protein
and urine NAG after 8 weeks. However, the levels of
urine protein and urine NAG were lower in the Adria-
mycin-induced nephropathy rats treated with QGYS.
Proteinuria, a marker of Adriamycin-induced nephrop-
athy, was 75% lower in group Ⅳ after 8 weeks, which
is more effective than previous reports in glomerulone-
phritic rats.12 The efficacy of QGYS on NAG was sig-
nificantly better than benazepril. Renal staining for
Col-Ⅳ and FN was more intense in group Ⅱ than
that in each other group. In contrast, staining for
Col-Ⅳ and FN was lower after treatment with either
QGYS or benazepril compared with groupⅡ. Earlier
application of QGYS had a protective effect on renal
function and structure. Its mechanism might have con-
tributed to the reduction of albuminuria and ECM.
Our research also demonstrated that the expression
and activity of MMP-9 was lower, while the expression
of TIMP-1 was higher. The ratio of TIMP-1/MMP-9
was notably higher in the control group, indicating
that the impairment of matrix degradation contributed
to the accumulation of ECM in Adriamycin-induced
Ⅰ Ⅱ Ⅲ Ⅳ
Col-Ⅳ
Figure 4 Expression of Col-Ⅳ and FN in the kidney 56 days after injection of Adriamycin
GroupⅠ as control group did not establish nephropathy model. GroupsⅡ,Ⅲ, andⅣ were intravenously administered Adriamy-
cin (7.5 mg/kg) through the tail vein to establish nephropathy model. GroupⅣ was administered Qiguiyishen decoction (2 mL·
kg-1·d-1); groupⅢ was administered benazepril (10 mL·kg-1·d-1); and groupsⅠ,Ⅱ was administered water (2 mL·kg-1·d-1) once
daily for eight weeks. FN: fibronectin; Col-Ⅳ: collagen Ⅳ. aP<0.05, compared with group Ⅰ; bP<0.05, compared with group Ⅱ;
and cP<0.05, compared with groupⅢ.
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Table 2 Levels of TGF-β1, MMP-9, and TIMP-1 after 56 days ( xˉ ±s)
Group
Ⅰ
Ⅱ
Ⅲ
Ⅳ
n
8
8
8
8
TGF-β1
0.169±0.015
0.491±0.034
0.285±0.042a
0.187±0.026ab
MMP-9
0.456±0.061
0.203±0.035
0.274±0.042a
0.314±0.028ab
TIMP-1
0.202±0.015
0.348±0.026
0.273±0.038a
0.240±0.030ab
Notes: groupⅠ as control group did not establish nephropathy model. GroupsⅡ,Ⅲ, andⅣ were intravenously administered Adriamy-
cin (7.5 mg/kg) through the tail vein to establish nephropathy model. GroupⅣ was administered Qiguiyishen decoction (2 mL·kg-1·d-1);
group Ⅲ was administered benazepril (10 mL·kg-1·d-1); and groupsⅠ, Ⅱ was administered water (2 mL·kg-1·d-1) once daily for eight
weeks. TGF-β1: transforming growth factor-β1; MMP-9: matrix metalloproteinases-9; TIMP-1: tissue inhibitor of metalloproteinase-1. aP<
0.05, compared with groupⅡ; bP<0.05, compared with groupⅢ.
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nephropathy. Benazepril is an angiotensin-converting
enzyme inhibitor. Not only does it reduce proteinuria
and decrease mesangial cell proliferation, it also adjusts
the expression and activity of MMPs/TIMPs, main-
tains the dynamic balance of renal MMPs/TIMPs, and
inhibits the accumulation of ECM.13
In conclusion, QGYS alleviated kidney injury in rats
with Adriamycin-induced nephropathy by decreasing
the accumulation of ECM and reversing the imbalance
of TIMP/MMP. This suggests that the decreasing of
ECM by QGYS might play an important role in allevi-
ating renal injury. QGYS might be a promising medica-
tion for the treatment of chronic kidney disease.
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